A Phase 2 interventional study of IMB-1018972 and Placebo in Ischemia and Coronary Artery Disease, sponsored by Imbria Pharmaceuticals, Inc.. Completed at 3 sites in 3 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-23.
Sponsored by Imbria Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Ischemia with a site in Denmark — 4 open to participants now, 5 under way, 1 of them phase 3. Ischemia · Denmark.
Among the 21 studies in Ischemia with a site in Denmark, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 2, and was the 15th registered.
545 studies on the registry are indexed under Ischemia; 72 are open to participants now.
Browse Ischemia studies →4 of the 21 studies in Ischemia with a site in Denmark are open now. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+ · Healthy volunteers
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Denmark, Australia, Austria and 5 more countries
Ages 6 mo–17 yrs
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 45 Ischemia studies recruiting now, 35 (78%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 4 · Phase 4 1
First in 1999; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 74 across 356 interventional studies indexed under Ischemia.
Median enrollment 67 across the 16 interventional studies, 40 across the 5 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 21 have an industry lead sponsor. The 10 most frequent:
Imbria Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Imbria Pharmaceuticals, Inc. has 1 study filed under Ischemia — fewer than ten, so there is no comparison to draw.
1 of the studies in Ischemia with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06322862Rigshospitalet, DenmarkFLuorescence Guided Assessment of Mesenteric Ischemia in Emergency Surgery | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Ischemia with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and tolerability of IMB-1018972 in subjects with obstructive CAD and inducible ischemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: IMB-1018972
Drug: Placebo
Modified release (MR) oral tablet
Matching oral tablet
Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs
Time frame: Randomization through Week 10 Safety Follow-up
Change in number of ischemic segments during hyperemia (ischemia defined as absolute MBF ≤2.0 ml/kg/min) as measured by adenosine stress 15O-H2O PET
Ischemia score defined on the basis of absolute hyperemic MBF as: (1) MBF 2.0-2.3 ml/g/min; (2) 1.7- 2.0 ml/g/min; (3) MBF \<1.7 ml/g/min
Time frame: Baseline through Week 8
Change in total ischemia burden measured as ischemia score summed across all segments as measured by adenosine stress 15O-H2O PET
Time frame: Baseline through Week 8
Change in inducible perfusion defect expressed as % of myocardium as measured by adenosine stress 15O-H2O PET
Time frame: Baseline through Week 8
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2021 to primary completion in Sep 2023, 28 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ninerafaxstat
Imbria Pharmaceuticals, Inc.